Biomarin Pharmaceutical News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

23.02.22	Form 8-K 1048477 (RSS)
17.02.22	BioMarin Provides Updates on Progress in Gene Therapy Programs (PR Newswire)
17.02.22	Form S-8 1048477 (RSS)
16.02.22	BioMarin to Participate in Two Upcoming Virtual Investor Conferences (PR Newswire)
14.02.22	Form 8-K 1048477 (RSS)
10.02.22	BioMarin to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Wednesday, February 23 at 4:30pm ET (PR Newswire)
09.02.22	BioMarin To Sell Rare Pediatric Disease PRV For $110 Mln (RTTNews)
09.02.22	BioMarin Sells Priority Review Voucher for $110 Million (PR Newswire)
07.02.22	Form 4 1048477 (RSS)
04.02.22	BioMarin Announces Oral Presentation of 2-Year Analysis of Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A at 15th Annual Congress of European Association for Haemophilia and... (PR Newswire)
02.02.22	BioMarin Demonstrates Enduring Commitment to Advancing the Standard of Care in Hemophilia A at 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) Februar... (PR Newswire)
19.01.22	Form 4 1048477 (RSS)
10.01.22	BioMarin : Bleed Control In Phase 3 Study Of Valoctocogene Roxaparvovec On Severe Hemophilia A (RTTNews)
09.01.22	BioMarin Announces Stable and Durable Annualized Bleed Control in the Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Eff... (PR Newswire)
05.01.22	Form 3 1048477 (RSS)
04.01.22	BioMarin to Participate in Two Virtual Investor Conferences in January (PR Newswire)
17.12.21	Form 4 1048477 (RSS)
16.12.21	BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases (PR Newswire)
15.12.21	BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of Directors (PR Newswire)
15.12.21	Form 8-K 1048477 (RSS)
15.12.21	ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important December 22 Deadline in Securities Class Act... (PR Newswire)
05.12.21	ROSEN, RESPECTED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important December 22 Deadline in Securities Class Action - BMRN (PR Newswire)
30.11.21	BioMarin to Hold Virtual R&D Day at 11:00am ET Today (PR Newswire)
29.11.21	BioMarin to Participate in Two Upcoming Virtual Investor Conferences (PR Newswire)
24.11.21	ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors with Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action - BMRN (PR Newswire)
19.11.21	FDA Approves BioMarin's Drug To Treat Dwarfism (RTTNews)
19.11.21	BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates (PR Newswire)
15.11.21	Entos and BioMarin Enter into Agreement for Product Candidates Incorporating Entos' Fusogenix Drug Delivery Platform (PR Newswire)
06.11.21	ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - BMRN (PR Newswire)
29.10.21	Biotech Stocks Facing FDA Decision In November 2021 (RTTNews)
27.10.21	BioMarin Lifts FY Guidance Driven By Product Demand (RTTNews)
27.10.21	Biomarin Pharmaceutical Inc. Q3 Earnings Summary (RTTNews)
27.10.21	BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates (PR Newswire)
26.10.21	ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BMRN (PR Newswire)
25.10.21	BioMarin to Participate in Four Upcoming Virtual Investor Conferences (PR Newswire)
12.10.21	BioMarin to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, October 27 at 4:30pm ET (PR Newswire)
04.10.21	BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical Operations (PR Newswire)
06.09.21	BioMarin Pharma Reports FDA's Clinical Hold On BMN 307 Phearless Phase 1/2 Study (RTTNews)
06.09.21	U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings (PR Newswire)
27.08.21	BioMarin Pharma Announces Approval For VOXZOGO In Europe - Quick Facts (RTTNews)
27.08.21	European Commission Approves BioMarin's VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close (PR Newswire)
25.08.21	BioMarin to Participate in Three Upcoming Virtual Investor Conferences (PR Newswire)
28.07.21	EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q2 Earnings Report (RTTNews)
28.07.21	BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates (PR Newswire)
21.07.21	BioMarin's Long-term Clinical Data On Severe Hemophilia A Show Continued, Clinical Benefit (RTTNews)
21.07.21	BioMarin Announces Oral Presentation at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress with 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene... (PR Newswire)
19.07.21	BioMarin Late-stage Trial On Valoctocogene Roxaparvovec Shows Superiority To Prophylaxis (RTTNews)
19.07.21	BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A at International Societ... (PR Newswire)
15.07.21	EMA Validates BioMarin' MAA For Valoctocogene Roxaparvovec To Treat Severe Hemophilia A (RTTNews)
15.07.21	European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

16.09.24		NASDAQ Composite aktuell: NASDAQ Composite schlussendlich im Minus
16.09.24		NASDAQ-Handel So entwickelt sich der NASDAQ Composite am Nachmittag
16.09.24		Anleger in New York halten sich zurück: NASDAQ Composite am Montagmittag schwächer
16.09.24		Verluste in New York: NASDAQ Composite verliert zum Start
06.08.24		Freundlicher Handel in New York: NASDAQ Composite zum Handelsende im Plus
06.08.24		Freundlicher Handel: NASDAQ Composite am Nachmittag freundlich
06.08.24		Handel in New York: NASDAQ Composite mittags mit grünem Vorzeichen
06.08.24		Börse New York in Grün: NASDAQ Composite zum Start des Dienstagshandels in Grün